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Abstract 
Noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists can 
produce positive and negative symptomatology as well as impairment of 
cognitive function that closely resemble those present in schizophrenia. In rats, 
these drugs induce a behavioral syndrome (characterized by hyperlocomotion 
and stereotypies), an enhanced glutamatergic transmission in the medial 
prefrontal cortex, and damage to retrosplenial cortical neurons in adult rats, 
which was measured as the induction of the stress protein 72/73 kDa heat 
shock protein (Hsp72/73). In the present work we have examined the existence 
of possible differences among different antipsychotic drugs in their capacity to 
block immunolabeling of Hsp72/73 in the retrosplenial cortex of the rat induced 
by the potent NMDA receptor antagonist, MK-801. In addition, the effects of 
selective monoaminergic agents were also studied to delineate the particular 
receptors responsible for the actions of antipsychotic drugs. Pretreatment with 
clozapine, chlorpromazine, olanzapine, ziprasidone -and to a lesser extent 
haloperidol- reduced the formation of Hsp72/73 protein in the rat retrosplenial 
cortex after the administration of MK-801. In addition, antagonism at dopamine 
D2 (raclopride), 5-HT2A (M100907) and 1-adrenoceptors (prazosin) as well as 
agonism at 5-HT1A receptors (BAY x 3702) also diminished the MK-801-induced 
number of cells labeled with Hsp72/73. Each of these effects may contribute to 
antipsychotic action. The results suggest that the efficacy of atypical 
antipsychotic drugs in the clinic may result from a combined effect on 5-HT2A, 5-
HT1A and 1-adrenergic receptors added to the classical dopamine D2 receptor 
antagonism. 
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INTRODUCTION 
Noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists, 
such as phencyclidine (PCP) and ketamine, can produce positive and negative 
symptomatology as well as impairment of cognitive function in humans that 
closely resemble those present in schizophrenia [1,2]. MK-801 is a 
noncompetitive NMDA receptor antagonist that produces hyperlocomotion and 
stereotypies in rodents [3,4], behaviors that are regarded as representative of 
the positive symptoms of schizophrenia [5,6]. In addition, noncompetitive NMDA 
receptor antagonists such as phencyclidine (PCP) and MK-801 also produce 
neuronal vacuolization in rats that was confined to layer III of retrosplenial 
cortex [7,8]. To explain the paradoxical effect of these agents, it was 
hypothesized that NMDA receptor antagonists would predominantly reduce 
GABAergic influence to pyramidal neurons in the retrosplenial cortex, thus 
activating major excitatory output that would ultimately lead to excitotoxicity 
induced by excessive release of glutamate [9]. This process of glutamatergic 
disinhibition has been recently confirmed in the prefrontal cortex [10]. As a likely 
response to the overexcitability of glutamatergic transmission, PCP, ketamine 
and MK-801 also trigger the synthesis of 70 KDa heat shock protein (Hsp70), 
which constitutes a reliable marker of reversible neuronal damage [11-14]. This 
Hsp70 response is also limited to putative pyramidal neurons localized to layer 
III of retrosplenial cortex [15]. It is possible that the same neurotoxic mechanism 
that caused vacuolization at earlier stages (4-12 hours) was also responsible for 
the later formation of Hsp72/73 (24-48 hours) after NMDA receptor blockade. 
The retrosplenial cortex corresponds to Brodmann’s areas 26/29/30 and is 
heavily connected to orbital and dorsolateral prefrontal cortex. It is the cortical 
region most consistently activated by emotionally salient stimuli. In addition, 
abnormal activity of the retrosplenial cortex has been observed in 
neuropsychiatric diseases that are associated with impairment of emotional 
responses [16]. 
Although it is not known whether these neuropathological alterations 
evoked by NMDA receptor antagonists take place in the human brain, the 
observation that these agents recreate schizophrenia symptoms [1,2] led some 
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investigators to postulate that such changes may also occur in NMDA receptor 
antagonist-induced psychosis and perhaps in the schizophrenia brain [7,17]. 
 Heat shock proteins are a group of highly conserved proteins that have a 
strong cytoprotective action and are inducible under different stressful 
conditions. As a matter of fact, Hsp72 is the most important inducible form of 
Hsp70 family. In previous studies we have shown that MK-801 enhanced 
glutamate release in the prefrontal cortex [18,19]. Thus, in the conditions of the 
present study, an enhanced Hsp72/73 synthesis would protect neurons from the 
neuronal injury caused by an excessive glutamate release after NMDA receptor 
blockade. We have also evidenced that classical and atypical antipsychotic 
drugs blocked the increase in glutamate efflux in the medial prefrontal cortex 
(mPFC) caused by MK-801, whereas only the latter class of drugs was able to 
additionally block the increased efflux of serotonin (5-HT) [18,20]. We proposed 
[19,20] that typical antipsychotics would prevent the MK-801-induced excessive 
glutamatergic transmission by increasing GABAergic transmission via a 
mechanism based on their D2 antagonism properties. On the other hand, it has 
been shown that atypical antipsychotic drugs may further act on 5-HT2A, 5-HT1A 
and 1-adrenoceptors present in pyramidal cells (including those projecting to 
the dorsal raphe nucleus), which would inhibit an excessive activation of these 
cells. 
 The ability of NMDA receptor antagonists to induce Hsp72/73 and exert 
neurotoxic effects in the retrosplenial cortex has been known for some time, as 
has the ability of certain antipsychotic drugs to prevent such damage. However, 
the receptor mechanisms explaining the prevention of this toxicity by such drugs 
have not been examined. Therefore, the aim of the present work was to 
examine the existence of possible differences among various antipsychotic 
drugs in their capacity to block the formation of Hsp72/73 in the retrosplenial 
cortex of the rat induced by MK-801. In addition, the effects of selective 
monoaminergic agents were also studied to delineate the particular receptors 
implicated in the action of antipsychotic drugs. Haloperidol and chlorpromazine 
were used as typical antipsychotics. Clozapine, olanzapine and ziprasidone 
were used as atypical antipsychotics. The selective monoaminergic agents 
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used were raclopride (dopamine D2-like receptor antagonist), M100907 (5-HT2A 
receptor antagonist), BAY x 3702 (5-HT1A receptor agonist) and prazosin (1-
adrenoceptor antagonist). The doses of these compounds were selected 
according to previous work in the literature [21] and taking into consideration the 
in vivo occupancy of the monoamine receptors studied. 
 
MATERIALS AND METHODS 
Animals 
Fifty two male Wistar rats (Charles River Laboratories, Spain) weighing 
300 ± 15 g were used (four animals in each group). They were kept on a 12 h 
light/dark cycle (lights on at 07:00) and housed three per cage with food and 
water available ad libitum. All experimental procedures were carried out in strict 
accordance with the European Communities Council Directive of 24 November 
1986 (86/609/EEC), and were approved by the Institutional Animal Care and 
Use Committees. 
 
Drug treatments 
Dizocilpine maleate (MK-801), chlorpromazine hydrochloride, and 
M100907 were purchased from Sigma-Aldrich (Tres Cantos, Spain). Clozapine, 
olanzapine, haloperidol, ziprasidone hydrochloride, raclopride, and prazosin 
hydrochloride were from Tocris (Bristol, UK). BAY x 3702 was generously 
donated by Bayer AG (Wuppertal, Germany). MK-801, prazosin and BAY x 
3702 were dissolved in saline. All other drugs were dissolved in a few drops of 
glacial acetic acid and then diluted with saline, which was used as vehicle for 
systemic administration. When it was necessary, the pH of the final 
concentrations was adjusted to ~7.0 with NaHCO3. All antipsychotic drugs and 
monoaminergic agents (or vehicle) were administered subcutaneously 1 h 
before MK-801 that was injected intraperitoneally. Control rats received vehicle 
followed 1 h later by saline. The dose of MK-801 (1 mg/kg) was chosen 
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because it produced maximal Hsp72/73 immunoreactivity when measured 24 h 
later [11]. 
 
Hsp72/73 immunohistochemistry 
All rats were deeply anesthetized with 60 mg/kg sodium pentobarbital 24 
h after the injection of MK-801 or saline, and perfused transcardially with cold 
heparinized saline followed by 4% paraformaldehyde in 0.1 M pH = 7.4 
phosphate buffered saline (PBS, 100 ml/100 g body weight). Each brain was 
removed immediately, post-fixed in the same fixative for 24 h at 4 °C, and then 
coronal sections of 30 µm were cut in a vibratome. Three sequential sections for 
each rat were collected free floating. Immunohistochemistry was performed 
according to Planas et al. [22]. Briefly, sections were incubated free floating in 
PBS including 0.2% Triton X-100, 0.2% gelatin and 3% horse serum for 2 h at 
room temperature followed by overnight incubation with mouse monoclonal anti-
Hsp72/73 antibody (Cat No HSP01, Clone W27, Calbiochem, CA, USA) diluted 
1:500 in PBS containing 0.2% Triton X-100, 0.2% gelatin and 1% horse serum. 
Hsp72 is the most prominent inducible form of Hsp70 family. Sections were 
then incubated in rat absorbed biotinylated horse anti-mouse IgG antibody 
(Vector Laboratories, CA, USA) diluted 1:200 for 2 h, followed by the avidin-
biotin complex at a dilution of 1:100 for 1 h (ABC kit Vectastain®, Vector 
Laboratories). The antibody reaction was carried out with 0.05% 
diaminobenzidine in 0.01% hydrogen peroxide. Several sections were 
incubated in the absence of the primary antibody as a false positive 
immunoreaction control. Sections were mounted onto gelatin-coated slides with 
Entellan®. 
 
Cell counting and statistical analysis 
The total number of Hsp72/73 positive cells was counted bilaterally in the 
entire retrosplenial cortex of the sections, using an Olympus BX51 Stereo 
Microscope (Tokio, Japan). Cell counting was performed blind to treatment, 
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using Visiopharm Integrator System software (Visiopharm A/S, Denmark). 
Measurements were performed in triplicate and the values are expressed as 
mean ± SEM of four animals per group. Statistical differences between groups 
were analyzed by one-way analysis of variance (ANOVA) followed by post hoc 
Newman–Keuls multiple comparison tests. Statistical calculations were made 
using GraphPad Prism software (La Jolla, USA). The level of significance was 
set at p < 0.05. 
 
RESULTS 
Representative photomicrographs of the effects of antipsychotic drugs 
and monoaminergic agents on the MK-801-induced formation of Hsp72/73 
protein in the retrosplenial cortex are depicted in figures 1 and 3, respectively. A 
thorough analysis of brain tissue sections showed that, under the conditions of 
the present study, no Hsp72/73 immunolabeling was detected after MK-801 in 
any other brain area (data not shown). Control rats that were not given MK-801 
did not show any cell positive for Hsp72/73 (Fig. 1C). 
Effects of antipsychotic drugs 
The doses of antipsychotic drugs were chosen from an excellent 
previous work in the literature that showed a clinically relevant occupancy of 
several monoaminergic receptors [21]. This occupancy data is depicted in Table 
1. The administration of antipsychotic drugs effectively blocked the formation of 
Hsp72/73 protein induced by MK-801 (Fig. 2), as demonstrated by the 
significant main effect of treatment (F6,28 = 39.01, p < 0.0001). Newman-Keuls 
post-hoc tests revealed that the effect of haloperidol was significantly lower than 
that of the rest of antipsychotic drugs (p < 0.001). It is of note that no single cell 
positive for Hsp72/73 was found after MK-801 in rats pretreated with clozapine, 
olanzapine or ziprasidone. 
 
Effects of monoaminergic agents 
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The administration of raclopride (1 mg/kg), M100907 (0.3 mg/kg), BAY x 
3702 (0.1 mg/kg), and prazosin (0.3 mg/kg) effectively blocked the formation of 
Hsp72/73 protein induced by MK-801 (Fig. 4), as demonstrated by the 
significant main effect of treatment (F5,25 = 44.50, p < 0.0001). Newman-Keuls 
post-hoc tests revealed no significant differences in the suppression of MK-801-
induced accumulation of Hsp72/73 protein among the four agents tested (p > 
0.05). 
 
DISCUSSION 
In previous work, we demonstrated that the systemic administration of MK-801 
produced an enhanced efflux of glutamate in the prefrontal cortex [18], which is 
likely the result of an increase in the firing rate of prefrontal, pyramidal neurons 
[23]. This excessive glutamatergic transmission is responsible for the induction 
of the cytoprotective Hsp70 family proteins [7]. However, MK-801-induced 
immunolabeling of Hsp70 is restricted to retrosplenial cortex as observed earlier 
[7,15,17]. Interestingly, MK-801 also caused a pronounced neuronal 
vacuolization and elevation of glucose utilization in the same brain area 
[7,24,25]. However, this excitotoxic cell damage is transient at doses of MK-801 
ranging from 0.6 to 2.5 mg/kg and irreversible necrotic changes are only 
observed after 5 mg/kg of MK-801 [26]. In the prefrontal cortex, induction of 
Hsp70 mRNA after PCP is detected only following amplification of the signal 
using reverse transcription-polymerase chain reaction [27]. It is possible that 
such a low level of Hsp70 induction, which is not sufficient for 
immunohistochemical protein detection, was related to the reported higher 
vulnerability of prefrontal cortex to neuronal injury [28,29]. Nonetheless, it has to 
be noticed that the retrosplenial cortex is a main hub of the so-called default 
mode network [30], the dysfunction of which may relate to impairments in 
attention and working memory seen in schizophrenia [31]. There are also 
connections of the retrosplenial cortex with prefrontal cortex, which may 
influence executive function. In fact, increased activity [32,33], and grey matter 
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volume deficits [34] in the retrosplenial cortex have been observed in 
schizophrenia. 
 From a pharmacological point of view, the main finding of the present 
study is that systemic administration of typical and atypical antipsychotics was 
able to reduce the neuronal injury (assessed by the expression of Hsp72/73) 
evoked by the NMDA receptor antagonist, MK-801. Previous work has shown 
that different antipsychotic drugs prevented the formation of Hsp70 induced by 
NMDA receptor antagonists (see below). However, to the best of our 
knowledge, this is the first study that compares the suppression of MK-801-
induced synthesis of Hsp72/73 produced by different antipsychotic drugs and 
selective monoaminergic agents acting at receptors for which such 
antipsychotic drugs exhibit affinity. It is of note that only the atypical 
antipsychotic drugs and chlorpromazine (see below) were able to totally abolish 
the appearance of Hsp72/73 immunoreactive cells in the retrosplenial cortex 
following MK-801. These results are in line with previous work using similar 
concentrations of the atypical drugs [21], and other studies using higher 
dosages [35] in female rats. In addition, clozapine and olanzapine also show 
superior efficacy than haloperidol in preventing MK-801-induced neurotoxicity 
measured as the number of vacuolized neurons [36-38]. In the present study, 
haloperidol reduced the number of Hsp72/73 positive cells, but to a lesser 
extent than the atypical antipsychotics tested, which also agrees with the 
observations reported above. Similar to our results, a reduced effect of 
haloperidol (compared to atypical antipsychotic drugs) in the expression of 
Hsp72/73 after PCP has been observed previously [39]. The effect of 
haloperidol is likely attributable to its blockade of dopamine D2-like receptors 
because a similar effect was obtained with a dose of raclopride that has a 
comparable occupancy of such receptors [40]. The case of chlorpromazine 
merits a comment since, although it is considered a typical antipsychotic with a 
characteristic high dopamine D2-like antagonistic activity, it also blocks a 
substantial proportion of 5-HT2A receptors at the dose administered in the 
present study [41]. Thus, it is conceivable that the effect of chlorpromazine 
resembled that of atypical antipsychotics drugs due to its blockade of 5-HT2A 
10 
 
receptors. Given that the doses of clozapine, olanzapine and ziprasidone 
appear to occupy a similar number of dopamine D2-like receptors in the brain, 
their superior efficacy in preventing MK-801-induced formation of Hsp72/73 
protein must likely be accounted for by actions at other monoaminergic 
receptors. Clearly, their comparable occupancy of 5-HT2A receptors, similar to 
that of M100907 [42,43], underscores the importance of 5-HT2A receptor 
blockade in these effects. BAY x 3702 is a potent 5-HT1A receptor agonist, 
which is purported to have a 100% occupancy at the dose used [44]. It 
effectively reduced the number of Hsp72/73-labeled neurons induced by MK-
801. Among the atypical antipsychotics tested, only clozapine and ziprasidone 
possess 5-HT1A agonistic properties [45]. However, in the present conditions 
the occupancy of 5-HT1A receptors by ziprasidone is less than 5% [46]. 
Consequently, an action on 5-HT1A receptors can be only attributable to 
clozapine. In a similar way, prazosin, which is a very potent antagonist that has 
a ~60% occupancy of 1-adrenoceptors in the present conditions [47], almost 
fully suppress the number of Hsp72/73 positive cells elicited by the 
administration of MK-801. Haloperidol, chlorpromazine, and clozapine have 
nanomolar affinity for 1-adrenoceptors [48,49]. However, in the experimental 
conditions of the present study, the protective effect of 1-adrenoceptor 
antagonism can only be attributed to clozapine (there is no data available on 
chlorpromazine) because it blocks a similar amount of 1-adrenoceptors than 
prazosin [47]. Interestingly, the blockade of 1-adrenoceptors by the antagonist 
prazosin potentiated the antipsychotic-like effect of the dopamine D2 receptor 
antagonist, raclopride, [50]. Finally, the action of the drugs and agents 
described herein can be easily explained by the presence of 5-HT2A [51], 5-HT1A 
[52], dopamine D2 [53], and 1-adrenergic receptors [54] in the retrosplenial 
cortex. 
 In summary, we have shown that antagonism at dopamine D2, 5-HT2A 
and 1-adrenoceptors as well as agonism at 5-HT1A receptors seem to be 
crucial for conferring protection against the neurotoxicity of MK-801. Our results 
indicate that similar to clozapine, pretreatment with chlorpromazine, olanzapine, 
ziprasidone -and to a lesser extent haloperidol- protects against the formation of 
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Hsp72/73 protein in the rat retrosplenial cortex after the administration of MK-
801. The suppression of the expression of Hsp72/73 induced by MK-801 may 
be implicated in the ability of antipsychotic drugs to prevent similar changes that 
may occur in the schizophrenia brain. It is possible that the efficacy of 
antipsychotic drugs in the clinic may result from a combined effect on dopamine 
D2, 5-HT2A, 5-HT1A and 1-adrenergic receptors. 
 
 
ABBREVIATIONS 
ANOVA = Analysis of Variance 
GABA  =  ɣ-Aminobutyric acid 
Hsp  =  Heat shock protein 
5-HT  =  Serotonin 
IgG  =  Immunoglobulin G 
MK-801 =  Dizocilpine 
mPFC  =  Medial prefrontal cortex 
NMDA =  N-methyl-D-aspartate 
PBS  =  Phosphate-buffered saline 
PCP  =  Phencyclidine 
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Table 1. Percentage of monoamine receptor occupancy of the different antipsychotic drugs at the doses used in the present study. 
Antipsychotic Drug 
(dose) Dopamine D2 5-HT2A 5-HT1A 1-adrenergic 
Clozapine 
(5 mg/kg) 
20-30% 
[40,55] 
 
70% 
[55] 
40% 
[55,56] 
 
60% 
[47] 
Olanzapine 
(5 mg/kg) 
50-60% 
[40,41] 
 
60-80% 
[41,57] 
 
NA NA 
Ziprasidone 
(10 mg/kg) 
50% 
[40] 
80% 
[58] 
Negligible 
[46] 
Negligible 
[59] 
Haloperidol 
(0.1 mg/kg) 
50% 
[40,55] 
 
<10% 
[55] 
Negligible 
[55] 
<10% 
[47,55] 
 
Chlorpromazine 
(5 mg/kg) 
40% 
[41] 
40% 
[41] NA NA 
Data taken or estimated from references given between parentheses. 
NA, data not available. 
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FIGURE LEGENDS 
 
Figure 1: Representative photomicrographs of the immunolabeling of 
Hsp72/73 induced by MK-801 in the layer III of the retrosplenial cortex of a 
male rat (A, B) and its blockade by the systemic administration of clozapine 
(D), haloperidol (E), olanzapine (F), chlorpromazine (G) and ziprasidone (H). 
The injection of vehicle (C) did not cause induction of Hsp72. Scale bars, 100 
µm. 
 
Figure 2: Blockade of the MK-801-induced number of Hsp72/73 cells by 
pretreatment with 0.1 mg/kg haloperidol (HAL), 5 mg/kg chlorpromazine (CPZ), 
5 mg/kg clozapine (CLZ), 5 mg/kg olanzapine (OLZ), and 10 mg/kg 
ziprasidone (ZPS). Data expressed as mean ± SEM of four animals per group 
measured in triplicate. Statistical differences assessed by Newman-Keuls 
tests. 
 
Figure 3: Representative photomicrographs of the immunolabeling of 
Hsp72/73 induced by MK-801 in the layer III of the retrosplenial cortex of a 
male rat (A) and its blockade by the systemic administration of raclopride (C), 
M100907 (D), BAY x 3702 (E), and prazosin (F). The injection of vehicle (B) 
did not cause induction of Hsp72. Scale bar, 100 µm. 
 
Figure 4: Blockade of the MK-801-induced number of Hsp72/73 cells by 
pretreatment with 1 mg/kg raclopride (RAC), 0.3 mg/kg M100907 (M100), 0.1 
mg/kg BAY x 3702 (BAY), and 0.3 mg/kg prazosin (PRZ). Data expressed as 
mean ± SEM of four animals per group measured in triplicate. Statistical 
difference assessed by Newman-Keuls test. 
 




